These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
444 related articles for article (PubMed ID: 32983132)
1. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies. Siegler EL; Kenderian SS Front Immunol; 2020; 11():1973. PubMed ID: 32983132 [TBL] [Abstract][Full Text] [Related]
2. Reactions Related to CAR-T Cell Therapy. Miao L; Zhang Z; Ren Z; Li Y Front Immunol; 2021; 12():663201. PubMed ID: 33995389 [TBL] [Abstract][Full Text] [Related]
3. Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy. Hughes AD; Teachey DT; Diorio C Semin Immunopathol; 2024 Jul; 46(3-4):5. PubMed ID: 39012374 [TBL] [Abstract][Full Text] [Related]
4. Need for standardization of cytokine profiling in CAR T cell therapy. Biery DN; Turicek DP; Diorio C; Schroeder BA; Shah NN Mol Ther; 2024 Sep; 32(9):2979-2983. PubMed ID: 38532629 [TBL] [Abstract][Full Text] [Related]
5. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment. Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K Front Immunol; 2021; 12():611366. PubMed ID: 33708205 [TBL] [Abstract][Full Text] [Related]
6. Management of T-Cell Engaging Immunotherapy Complications. Varadarajan I; Lee DW Cancer J; 2019; 25(3):223-230. PubMed ID: 31135530 [TBL] [Abstract][Full Text] [Related]
7. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. Xiao X; Huang S; Chen S; Wang Y; Sun Q; Xu X; Li Y J Exp Clin Cancer Res; 2021 Nov; 40(1):367. PubMed ID: 34794490 [TBL] [Abstract][Full Text] [Related]
8. Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities. Schroeder T; Martens T; Fransecky L; Valerius T; Schub N; Pott C; Baldus C; Stölzel F Intensive Care Med; 2024 Sep; 50(9):1459-1469. PubMed ID: 39172238 [TBL] [Abstract][Full Text] [Related]
10. Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia. Hong F; Shi M; Cao J; Wang Y; Gong Y; Gao H; Li Z; Zheng J; Zeng L; He A; Xu K J Cell Mol Med; 2021 Dec; 25(24):11063-11074. PubMed ID: 34734474 [TBL] [Abstract][Full Text] [Related]
12. A Primer on Chimeric Antigen Receptor T-cell Therapy-related Toxicities for the Intensivist. Ong SY; Baird JH J Intensive Care Med; 2024 Oct; 39(10):929-938. PubMed ID: 37899577 [TBL] [Abstract][Full Text] [Related]
13. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. Freyer CW; Porter DL J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558 [TBL] [Abstract][Full Text] [Related]
14. Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy. Walton ZE; Frigault MJ; Maus MV Expert Opin Pharmacother; 2024 Feb; 25(3):263-279. PubMed ID: 38588525 [TBL] [Abstract][Full Text] [Related]
16. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy. Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616 [TBL] [Abstract][Full Text] [Related]
17. Continuous blood purification successfully treated severe cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy: A case report. Zhang F; Jia XL; Zuo YX; Lu AD; Zhang PF; Xue L; Zhang LP Pediatr Blood Cancer; 2022 Aug; 69(8):e29563. PubMed ID: 35044056 [No Abstract] [Full Text] [Related]